News
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, seeking to tap into a market that is ...
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...
China has leveraged its dominance over rare earths for Nvidia chips; however, this expert says world isn't decoupling, it is ...
EUROPEAN shares ended lower on Tuesday, dragged down by heavyweight financial and healthcare stocks as investors awaited news ...
Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...
By Sukriti Gupta, Sanchayaita Roy and Twesha Dikshit (Reuters) -European shares ended lower on Tuesday, dragged down by heavyweight financial and healthcare stocks as investors awaited news on a ...
By Mariam Sunny (Reuters) -U.S.-based Kailera Therapeutics and Chinese firm Jiangsu Hengrui Pharmaceuticals' experimental weight-loss drug has helped overweight patients lose up to 17.7% of body ...
Temasek spent $2 billion in April 2023 to raise its stake in Manipal to 59% from 18% in the biggest hospital sector deal ever ...
A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...
European shares closed lower on Friday, as losses in banks and healthcare stocks weighed at the end of a week marred by U.S. President Donald Trump's tariff announcements, with the European Union also ...
By Sanchayaita Roy, Sukriti Gupta and Shashwat Chauhan (Reuters) -European shares closed higher on Thursday, with mining and healthcare stocks the biggest boosts as investors watched for signs of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results